Targeted protein degradation by PROTACs

Pharmacology and Therapeutics

Volumn 174, Issue , 2017, Pages 138-144

  Neklesa, Taavi K ^a   Winkler, James D ^a   Crews, Craig M ^b,c  

^a Arvinas Inc   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cereblon; PROTAC; Targeted protein degradation; Undruggable proteome; VHL

Indexed keywords

CELL PROTEIN; PROTEASOME; ENZYME INHIBITOR; PROTEIN;

BIOAVAILABILITY; DRUG EXPOSURE; ENZYME INHIBITION; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; TISSUE DISTRIBUTION; UBIQUITINATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; MOLECULAR WEIGHT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; PROTEOLYSIS; UBIQUITINATION;

EID: 85013058483     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.02.027     Document Type: Review

References (50)

1. Advani, R.H., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B.,.. Smith, M., Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 30, 2012, 10.1200/JCO.2012.42.7906.
2. Askari, B.S., Krajinovic, M., Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomes. Current Genomics 11:8 (2010), 578–583, 10.2174/138920210793360925.
3. Banaszynski, L.A., Liu, C.W., Wandless, T.J., Characterization of the FKBP-rapamycin-FRB ternary complex. Journal of the American Chemical Society 127:13 (2005), 4715–4721.
4. Bobbin, M.L., Rossi, J.J., RNA interference (RNAi)-based therapeutics: Delivering on the promise?. Annual Review of Pharmacology and Toxicology 56 (2016), 103–122, 10.1146/annurev-pharmtox-010715-103633.
5. Bondeson, D.P., Mares, A., Smith, I.E.D., Ko, E., Campos, S., Miah, A.H.,.. Crews, C.M., Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology 11:8 (2015), 611–617, 10.1038/nchembio.1858.
6. Brundin, P., Melki, R., Kopito, R., Prion-like transmission of protein aggregates in neurodegenerative diseases. Nature Reviews. Molecular Cell Biology 11:4 (2010), 301–307, 10.1038/nrm2873.
7. Buckley, D.L., Gustafson, J.L., Van Molle, I., Roth, A.G., Tae, H.S., Gareiss, P.C.,.. Crews, C.M., Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. Angewandte Chemie (International Ed. in English) 51:46 (2012), 11463–11467, 10.1002/anie.201206231.
8. Buckley, D.L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J.L., Smith, I.E.,.. Crews, C.M., HaloPROTACS: Use of small molecule PROTACs to induce degradation of HaloTag fusion proteins. ACS Chemical Biology 10:8 (2015), 1831–1837, 10.1021/acschembio.5b00442.
9. Buckley, D.L., Van Molle, I., Gareiss, P.C., Tae, H.S., Michel, J., Noblin, D.J.,.. Crews, C.M., Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. Journal of the American Chemical Society 134:10 (2012), 4465–4468, 10.1021/ja209924v.
10. Cai, C., He, H.H., Chen, S., Coleman, I., Wang, H., Fang, Z.,.. Balk, S.P., Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20 (2011), 457–471, 10.1016/j.ccr.2011.09.001.
11. Chan, A.I., McGregor, L.M., Liu, D.R., Novel selection methods for DNA-encoded chemical libraries. Current Opinion in Chemical Biology 26 (2015), 55–61, 10.1016/j.cbpa.2015.02.010.
12. Crews, C.M., Targeting the undruggable proteome: The small molecules of my dreams. Chemistry & Biology 17:6 (2010), 551–555, 10.1016/j.chembiol.2010.05.011.
13. Culig, Z., Hoffmann, J., Erdel, M., Eder, I.E., Hobisch, A., Hittmair, A.,.. Klocker, H., Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer 81:2 (1999), 242–251, 10.1038/sj.bjc.6690684.
14. Das Thakur, M., Salangsang, F., Landman, A.S., Sellers, W.R., Pryer, N.K., Levesque, M.P.,.. Stuart, D.D., Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494:7436 (2013), 251–255, 10.1038/nature11814.
15. Deshaies, R.J., Protein degradation: Prime time for PROTACs. Nature Chemical Biology 11:9 (2015), 634–635, 10.1038/nchembio.1887.
16. Evans, E.K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M.T.,.. Westlin, W.F., Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. The Journal of Pharmacology and Experimental Therapeutics 346:2 (2013), 219–228, 10.1124/jpet.113.203489.
17. Feltham, R., Bettjeman, B., Budhidarmo, R., Mace, P.D., Shirley, S., Condon, S.M.,.. Day, C.L., Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. The Journal of Biological Chemistry 286:19 (2011), 17015–17028, 10.1074/jbc.M111.222919.
18. Fukui, S., Nakai, Y., Matsumoto, Y., Kagebayashi, Y., Samma, S., Investigation of incidence and risk factors of subcutaneous granulomas induced by injection of leuprorelin acetate. Hinyokika Kiyo. Acta Urologica Japonica 61:2 (2015), 55–59 (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25812594).
19. Gustafson, J.L., Neklesa, T.K., Cox, C.S., Roth, A.G., Buckley, D.L., Tae, H.S.,.. Crews, C.M., Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging. Angewandte Chemie International Edition, 54(33), 2015, 10.1002/anie.201503720.
20. He, R., Yu, Z., Zhang, R., Zhang, Z., Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacologica Sinica 35:10 (2014), 1227–1246, 10.1038/aps.2014.80.
21. 2 sensing. Science (New York, N.Y.) 292:5516 (2001), 464–468, 10.1126/science.1059817.
22. 2-regulated prolyl hydroxylation. Science (New York, N.Y.) 292:5516 (2001), 468–472, 10.1126/science.1059796.
23. Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A.M.,.. Miller, V.A., Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20:7 (2014), 1757–1767, 10.1158/1078-0432.CCR-13-2332.
24. Joseph, J.D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D.,.. Hager, J.H., A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discovery 3:9 (2013), 1020–1029, 10.1158/2159-8290.CD-13-0226.
25. Katayama, R., Khan, T.M., Benes, C., Lifshits, E., Ebi, H., Rivera, V.M.,.. Shaw, A.T., Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proceedings of the National Academy of Sciences of the United States of America 108:18 (2011), 7535–7540, 10.1073/pnas.1019559108.
26. Kim, S., Kim, T.M., Kim, D.-W., Go, H., Keam, B., Lee, S.-H.,.. Doebele, R., Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. Journal of Thoracic Oncology 8:4 (2013), 415–422, 10.1097/JTO.0b013e318283dcc0.
27. King, A.J., Arnone, M.R., Bleam, M.R., Moss, K.G., Yang, J., Fedorowicz, K.E.,.. Laquerre, S.G., Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PloS One, 8(7), 2013, e67583, 10.1371/journal.pone.0067583.
28. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T.,.. Levine, R.L., Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489:7414 (2012), 155–159, 10.1038/nature11303.
29. Lai, A.C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E.,.. Crews, C.M., Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angewandte Chemie (International Ed. in English) 55:2 (2016), 807–810, 10.1002/anie.201507634.
30. Leverson, J.D., Zhang, H., Chen, J., Tahir, S.K., Phillips, D.C., Xue, J.,.. Souers, A.J., Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death and Disease, 6(1), 2015, e1590, 10.1038/cddis.2014.561.
31. Linja, M.J., Savinainen, K.J., Saramäki, O.R., Tammela, T.L., Vessella, R.L., Visakorpi, T., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61:9 (2001), 3550–3555 (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11325816).
32. Link, J.O., Taylor, J.G., Xu, L., Mitchell, M., Guo, H., Liu, H.,.. Desai, M.C., Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. Journal of Medicinal Chemistry 57:5 (2014), 2033–2046, 10.1021/jm401499g.
33. Liu, J., Carmell, M.A., Rivas, F.V., Marsden, C.G., Thomson, J.M., Song, J.-J.,.. Hannon, G.J., Argonaute2 is the catalytic engine of mammalian RNAi. Science (New York, N.Y.) 305:5689 (2004), 1437–1441, 10.1126/science.1102513.
34. Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K.,.. Crews, C.M., Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chemistry & Biology 22:6 (2015), 755–763, 10.1016/j.chembiol.2015.05.009.
35. Martinez Molina, D., Nordlund, P., The cellular thermal shift assay: A novel biophysical assay for in situ drug target engagement and mechanistic biomarker studies. Annual Review of Pharmacology and Toxicology 56 (2016), 141–161, 10.1146/annurev-pharmtox-010715-103715.
36. Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M.,.. Harousseau, J.-L., Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. The Lancet. Oncology 12:5 (2011), 431–440, 10.1016/S1470-2045(11)70081-X.
37. Paez, J.G., Jänne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S.,.. Meyerson, M., EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science (New York, N.Y.) 304:5676 (2004), 1497–1500, 10.1126/science.1099314.
38. Preisler-Mashek, M.T., Solodin, N., Stark, B.L., Tyriver, M.K., Alarid, E.T., Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. American Journal of Physiology. Endocrinology and Metabolism 282:4 (2002), E891–E898, 10.1152/ajpendo.00353.2001.
39. Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A.M.K.,.. Coleman, K.G., PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proceedings of the National Academy of Sciences, 2016, 201521738, 10.1073/pnas.1521738113.
40. Rask-Andersen, M., Almén, M.S., Schiöth, H.B., Trends in the exploitation of novel drug targets. Nature Reviews Drug Discovery 10:8 (2011), 579–590, 10.1038/nrd3478.
41. Sakamoto, K.M., Kim, K.B., Kumagai, A., Mercurio, F., Crews, C.M., Deshaies, R.J., Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America 98:15 (2001), 8554–8559, 10.1073/pnas.141230798.
42. Samuels, Y., Waldman, T., Oncogenic mutations of PIK3CA in human cancers. Current Topics in Microbiology and Immunology 347 (2010), 21–41, 10.1007/82_2010_68.
43. Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J.L., Pedersen, K.,.. Baselga, J., Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:6 (2009), 803–814, 10.1038/onc.2008.432.
44. Schneekloth, J.S., Fonseca, F.N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., Crews, C.M., Chemical genetic control of protein levels: Selective in vivo targeted degradation. Journal of the American Chemical Society 126:12 (2004), 3748–3754, 10.1021/ja039025z.
45. Schneekloth, A.R., Pucheault, M., Tae, H.S., Crews, C.M., Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorganic & Medicinal Chemistry Letters 18:22 (2008), 5904–5908, 10.1016/j.bmcl.2008.07.114.
46. Shao, J., Diamond, M.I., Polyglutamine diseases: Emerging concepts in pathogenesis and therapy. Human Molecular Genetics, 2007, R115–R123, 10.1093/hmg/ddm213.
47. Suhr, O.B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J.,.. Melton, B., Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study. Orphanet Journal of Rare Diseases, 10(1), 2015, 109, 10.1186/s13023-015-0326-6.
48. Toure, M., Crews, C.M., Small-molecule PROTACS: New approaches to protein degradation. Angewandte Chemie (International Ed. in English) 55:6 (2016), 1966–1973, 10.1002/anie.201507978.
49. Winter, G.E., Buckley, D.L., Paulk, J., Roberts, J.M., Souza, A., Dhe-Paganon, S., Bradner, J.E., Phthalimide conjugation as a strategy for in vivo target protein degradation. Science, 348(6241), 2015.
50. Zengerle, M., Chan, K.-H., Ciulli, A., Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chemical Biology 10:8 (2015), 1770–1777, 10.1021/acschembio.5b00216.